Last reviewed · How we verify
Clamoxyl
At a glance
| Generic name | Clamoxyl |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immediate Restoration of a New Implant With High Primary Stability (NA)
- National Study on Listeriosis and Listeria
- Different Amoxicillin Treatment Regimens in Erythema Migrans Patients (PHASE3)
- APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) (PHASE2)
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clamoxyl CI brief — competitive landscape report
- Clamoxyl updates RSS · CI watch RSS
- Pfizer portfolio CI